In the specialized field of biochemical research, the study of G protein-coupled receptors has led to significant insights into cellular signaling. Among these, the par-4 agonist peptide has emerged as a vital tool for by X Han · 2018 · Cited by 35 — Thrombin, the most potent platelet agonist in vivo, activates human platelets through PAR1 (protease-activated receptor 1) and PAR4 investigators looking to understand the complex mechanisms of protease-activated receptors. As someone deeply intere PAR-4 Agonist Peptide, amide sted in the nuances of peptide science, I have spent significant time examining how these synthetic molecules serve as selective probes in experimental models.
Defining the PAR-4 Agonist Peptide
At its core, the Protease-activated receptor 4 (PAR4) is a fascinating subject of study. Unlike other receptors, PAR4 is uniquely activated by proteases generated during tissue damage. The PAR-4 agonist peptide, amide (PAR-4-AP; AY-NH2) is a cornerstone in this research. It is a highly selective tool, designed to mimic the tethered ligand of the receptor, allowing researchers to study signaling pathways without the broad-spectrum effects of endogenous enzymes.
When reviewing the literature, it is clear that AY-NH2 is a selective PAR4 receptor agonist peptide. In various *in vitro* studies, this peptide has demonstrated high efficacy, often cited with an EC50 of approximately 15 μM. Furthermore, variants such as the PAR-4 Agonist Peptide, amide TFA provide additional flexibility for researchers requiring different solubility profiles in their laboratory protocols.
Distinguishing Between PAR-4 and Other Signaling Pathways
A critical aspect of using a PAR-4 agonist peptide is its specificity. In many experimental setups, it is essential to ensure that the stimulation observed is exclusive to the target. Research confirms that the standard amide form has no effect on PAR-1 or PAR-2, making it a clean probe for isolating PAR4-specific mechanisms.
Comparatively, investigators often look at the PAR4 specific agonist peptide, AYPGKF. This sequence has been instrumental in probing signaling systems in both culture and tissue models. While GYPGQV does function as an agonist for PAR4, it is important to note that it requires a significantly higher concentration—often in the 200–500 μM range—to achieve similar levels of activity. This difference in potency highlights why the AYPGKF and AY-NH2 sequences remain the gold standard for high-fidelity research.
Experimental Observations and Insights
In the context of cellular resea PAR-4 agonist AYPGKF stimulates thromboxane rch, PAR-4 agonist peptide stimulates thromboxane production by human platelets. Observations show that the maximal response to this agonist is approximately half of that observed with full thrombin stimulation. This partial response is a key indicator for researchers mapping out the downstream effects of Protease-activated receptor 4 (PAR4) activity.
It is also worth noting the relationship between these molecules and other signaling agents. For instance, C4a is reported to be an agonist for both protease-activated receptor (PAR) 1 and PAR4 by J Yang · 2022 · Cited by 7 — Protease-activated receptor 4 (PAR4) is a promising drug target to improve the efficacy/safety window of antiplatelet agents. The native peptide in specific microvascular contexts, which adds a layer of complexity for those mapping receptor crosstalk. Similarly, while thrombin is a potent platelet agonist, the ability to use specific PAR4 agonists instead allows for a more granular view of how these receptors contribute to broader physiological responses.
Future Directions in Research
The scientific community continues to refine the use of these peptides and agonists. Much of the interest stems from the fact that PAR4 targeting is a safer strategy for preventing thro by RA Henriksen · 2002 · Cited by 46 — The results show that treatment of washed human platelets with the PAR-4 agonist AYPGKF stimulates a maximum of 40% to 60% of the thromboxane produced by 100 mbosis in experimental models, as compared to broad-spectrum inhibition. While clinical developments like BMS-986120—a novel oral PAR4 antagonist—are currently being explored for their potential to modul PAR-4 Agonist Peptide, amide. Agonist, 99.75%. PAR-4 Agonist Peptide, amide (PAR-4-AP; AY-NH2) is a proteinase-activated receptor-4 (PAR-4) agonist, which has ate these pathways, the fundamental wor Protease Activated Receptor (PAR) | Agonists Antagonists k begins with the PAR-4 Ago An optimized agonist peptide of protease-activated nist Peptide, amide.
Whether you are working with PAR4APs GY-NH2 and AY-NH2 or exploring the structural limits of PAR-4 agonist AYPGKF, the precision offered by these synthetic tools is unmatched. By focusing on the specific activation of these receptors, we gain a clearer picture of how cellular signaling functions in the presence of tissue-related proteases. It is a compelling area of study that underscores the power of targeted molecular intervention.